ArticleJournal of dental sciences2025
Intranasal administration of tissue inhibitor of metalloproteinase 1 extracted from stem cells from human exfoliated deciduous teeth-conditioned medium improves neurological outcomes and alpha-synuclein elimination in Parkinson's disease mice.
Article in Journal of dental sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Parkinson's disease (PD) remains a challenging neurodegenerative disorder, requiring the exploration of innovative therapeutic strategies. This study assessed the neuroprotective effects of stem cells from human exfoliated deciduous teeth-conditioned medium (SHED-CM) in a rotenone-induced mouse model of PD. Materials and methods: The SHED-CM, fractionated and purified via Fast Protein Liquid Chromatography (FPLC) into "yPD01", was administered intranasally to evaluate its impact on motor deficits, olfactory functions, and protein expressions in affected brain regions. Results: Upon intranasal delivery, yPD01 produced significant improvements to motor deficits and restoration of protein expressions associated with PD pathology, particularly in the olfactory bulb and substantial nigra. Intriguingly, the intranasal route exhibited efficacy akin to intravenous administration, highlighting its potential as a minimally invasive yet equally effective therapeutic approach. Further investigation indicated key components within yPD01, denoted as peaks P1 and P5, showcasing pivotal therapeutic effects. These components were linked to the interruption of alpha-synuclein aggregation and its clearance within specific brain cells affected by PD. Conclusion: Intranasally administered yPD01 shows neuroprotective potential for mitigating neurodegenerative symptoms, particularly in PD. The results provide valuable insights into potential mechanisms underlying the neuroprotective effects of SHED-CM and their implications for future therapeutic interventions in PD and related conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.